Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Norris

Showing results (481-490 of 531) with videos related to

Pageof 54
Sort By:
Cancer Research|May 20, 2016
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of DyskerinRosemary O'Brien, Sieu L Tran, Michelle F Maritz, et al.
Breast Cancer Research and Treatment|March 5, 2020
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancerKaitlyn J Andreano, Suzanne E Wardell, Jennifer G Baker, et al.
Oncotarget|June 19, 2016
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangementsKlaartje Somers, Daria A Chudakova, Shiloh M C Middlemiss, et al.
Nature Medicine|September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastomaAlexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
International Journal of Cancer|April 12, 2020
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancerMoonsun Jung, Jixuan Gao, Leanna Cheung, et al.
Cell Death and Differentiation|November 24, 2012
The histone deacetylase SIRT2 stabilizes Myc oncoproteinsP Y Liu, N Xu, A Malyukova, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivoJayne Murray, Emanuele Valli, Denise M T Yu, et al.
Leukemia|January 4, 2020
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesisLioubov Korotchkina, Denis Kazyulkin, Pavel G Komarov, et al.
British Journal of Cancer|June 1, 2022
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusionsNicola C Venn, Libby Huang, Lenka Hovorková, et al.
Pageof 54

Showing results (481-490 of 531) with videos related to

Sort By:
Pageof 54
Cancer Research|May 20, 2016
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of DyskerinRosemary O'Brien, Sieu L Tran, Michelle F Maritz, et al.
Breast Cancer Research and Treatment|March 5, 2020
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancerKaitlyn J Andreano, Suzanne E Wardell, Jennifer G Baker, et al.
Oncotarget|June 19, 2016
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangementsKlaartje Somers, Daria A Chudakova, Shiloh M C Middlemiss, et al.
Nature Medicine|September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastomaAlexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
International Journal of Cancer|April 12, 2020
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancerMoonsun Jung, Jixuan Gao, Leanna Cheung, et al.
Cell Death and Differentiation|November 24, 2012
The histone deacetylase SIRT2 stabilizes Myc oncoproteinsP Y Liu, N Xu, A Malyukova, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivoJayne Murray, Emanuele Valli, Denise M T Yu, et al.
Leukemia|January 4, 2020
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesisLioubov Korotchkina, Denis Kazyulkin, Pavel G Komarov, et al.
British Journal of Cancer|June 1, 2022
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusionsNicola C Venn, Libby Huang, Lenka Hovorková, et al.
Pageof 54